NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
Publication
, Journal Article
Thompson, JA; Schneider, BJ; Brahmer, J; Zaid, MA; Achufusi, A; Armand, P; Berkenstock, MK; Bermas, B; Braaten, T; Budde, LE; Chokshi, S ...
Published in: J Natl Compr Canc Netw
November 2024
The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell-engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
Duke Scholars
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2024
Volume
22
Issue
9
Start / End Page
582 / 592
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasms
- Medical Oncology
- Immunotherapy
- Immune Checkpoint Inhibitors
- Humans
- Drug-Related Side Effects and Adverse Reactions
- Disease Management
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Thompson, J. A., Schneider, B. J., Brahmer, J., Zaid, M. A., Achufusi, A., Armand, P., … Hang, L. (2024). NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw, 22(9), 582–592. https://doi.org/10.6004/jnccn.2024.0057
Thompson, John A., Bryan J. Schneider, Julie Brahmer, Mohammad Abu Zaid, Amaka Achufusi, Philippe Armand, Meghan K. Berkenstock, et al. “NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.” J Natl Compr Canc Netw 22, no. 9 (November 2024): 582–92. https://doi.org/10.6004/jnccn.2024.0057.
Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, et al. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov;22(9):582–92.
Thompson, John A., et al. “NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.” J Natl Compr Canc Netw, vol. 22, no. 9, Nov. 2024, pp. 582–92. Pubmed, doi:10.6004/jnccn.2024.0057.
Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, Berkenstock MK, Bermas B, Braaten T, Budde LE, Chokshi S, Crees ZD, Davies M, Deng C, Gesthalter Y, Jain M, Jain P, Jallouk A, Kaffenberger BH, Khalil M, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Prosek J, Reddy S, Reid P, Ryan J, Ryder M, Salman H, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Zucker S, Lyons M, Awotiwon A, Hang L. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov;22(9):582–592.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2024
Volume
22
Issue
9
Start / End Page
582 / 592
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasms
- Medical Oncology
- Immunotherapy
- Immune Checkpoint Inhibitors
- Humans
- Drug-Related Side Effects and Adverse Reactions
- Disease Management
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis